Abstract
Melasma is a common acquired disorder of disfiguring hyperpigmentation and has attracted increasing attention in the field of medical aesthetics due to its high risk for recurrence and difficulty in treatment. Low-fluence Q-switched Nd: YAG 1064 nm (LFQSNY) laser is a commonly used phototherapy clinical for melasma at present, however, the mechanism underlying the photomanipulation remains unclear. This study aims to elucidate the potential mechanisms underlying the LFQSNY laser treatment. LFQSNY laser irradiation significantly attenuated melanin production in cells via upregulating DHX9 and repressing TRIB3 through promoter binding. Furthermore, the laser reduced inflammatory factors and enhanced phagocytic activity in macrophages. Our findings reveal that LFQSNY laser inhibits melanogenesis and enhances anti-inflammation for improved pigment-clearance via non-thermal photobiomodulation.
Introduction
Melasma presents as stubborn, symmetric hyperpigmented patches, often resistant to traditional treatments. While high-energy "selective photothermolysis" was once the standard—aiming to shatter pigment with heat—it frequently caused rebound hyperpigmentation and inflammation in darker skin tones. Clinicians shifted toward "low-fluence" laser settings, which showed better efficacy with fewer side effects. However, the biological mechanism behind this success remained poorly understood. This research investigates how low-energy light modulates cellular signaling to inhibit pigment production and resolve inflammation without thermal damage.
Methodology
The study utilized a multi-faceted approach combining in vitro and in vivo models:
- Cellular Models: B16F10 murine melanoma cells were used to study pigment production, while RAW264.7 macrophages were used to investigate the inflammatory response.
- Animal Models: C57BL/6J mice provided in vivo validation for skin tissue observations.
- Analytical Techniques: Infrared thermography monitored temperature changes to confirm non-thermal effects. RNA-seq identified differentially expressed genes, and Dual-Luciferase assays confirmed the interaction between the protein DHX9 and the TRIB3 gene promoter.
- Genetic Validation: CRISPR/siRNA silencing was employed to "knock out" specific genes and confirm their role in the laser's therapeutic pathway.
Results and Discussion
Non-Thermal Photobiomodulation
A critical finding was the confirmation of a non-thermal mechanism. Infrared thermography demonstrated that low-fluence settings did not significantly raise the temperature of the treated cells, distinguishing this treatment from traditional heat-based laser surgery that relies on protein denaturation.
Biphasic Cellular Response
The study identified a biphasic response to laser energy. At optimal settings (e.g., 1.0 J/cm² with low passes), the laser acts as a biological signal (photobiomodulation) that preserves cell health. However, increasing the fluence or the number of passes leads to cytotoxicity and significant drops in cell viability.
The DHX9-TRIB3 Signaling Axis
The researchers discovered that the laser upregulates DHX9, an RNA helicase. DHX9 then acts as a transcriptional repressor for the TRIB3 gene. Suppressing TRIB3 effectively slows down the entire melanin "assembly line," including key enzymes like Tyrosinase (TYR), TYRP1, and TYRP2. This molecular "off switch" is a primary driver of the treatment's efficacy.
Anti-Inflammatory and Phagocytic Effects
Beyond inhibiting new pigment, the laser improves the "cleanup" of existing melanin. It reduces pro-inflammatory markers (TNF-α, IL-1β, NLRP3) in macrophages and shifts them toward a healing (M2-like) phenotype. This shift enhances the macrophages' ability to phagocytose (engulf) existing melanin granules, facilitating clearer skin.
Conclusion
This study provides a robust molecular framework for the clinical success of LFQSNY lasers in melasma treatment. By identifying the DHX9-TRIB3 axis and the anti-inflammatory role of macrophages, the research moves the field from empirical observation to mechanistic understanding. Future work should focus on validating these pathways in human skin models and assessing the long-term stability of the DHX9-mediated pigment suppression.
Reference: Dong, J., Yao, S., Wu, S. et al. Melanogenesis inhibition and anti-inflammation is essential for pigment-clearance in melasma treated by low-fluence Q-switched nd: YAG 1064 nm laser. Lasers Med Sci (2025).
Summary updated